Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
    • Media
  1. Home
  2. Investors

Press releases

15.07.2020

DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop innovative anti-...
17.06.2020

Issuance of a 3rd tranche of €1.5 million of notes convertible into new shares

DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...
04.05.2020

Alexis RIDEAU appointed Deputy Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships

• Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...
29.04.2020

2019 Annual results: A year of important milestones in both Antibiotics and Cosmetics activities

Significant achievements in antibiotic programs: Initiation of the Phase II trial testing DNV3837 as first-line treatment for severe C...
23.04.2020

Official launch of Luminity®, DEINOVE's new cosmetic active ingredient for a radiant complexion

Luminity® is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion...
03.04.2020

Issuance of a 2nd tranch of €1 million of notes convertible into new shares

DEINOVE immediately strengthens its cash position by €1 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses...
01.04.2020

DEINOVE obtains from Société Générale Factoring the pre-funding of its 2019 R&D Tax Credit receivable amounting to EUR 2.1 million

For the second year in a row, DEINOVE has called on Société Générale Factoring (SGF) to pre-finance its R&D Tax Credit receivable...
30.03.2020

In a climate of economic and industrial uncertainty, the collaboration agreement between Sharon Laboratories and Deinove will not be signed

The current health, economic and financial crisis creates too much uncertainty to enter into a long-term full partnership around a complete...
24.03.2020

DEINOVE updates its financial calendar

The 2019 financial results are postponed to April 29, 2020. At this stage, the other dates remain unchanged. DEINOVE (Euronext Growth Paris...
18.03.2020

Commercial launch of BIOME Oléoactif®, new cosmetic active co-developed by Deinove and Hallstar France

BIOME Oléoactif® is an exclusive active ingredient that regulates skin microbiota and reinforces skin barrier function, thanks to a unique...
  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

Investors

  • Corporate governance
    • Board of Directors
    • Executive Committee
  • DEINOVE Shares
  • Financial Calendar
  • Documentation Center
    • Financial Reports
    • Investors slide deck
    • Analyst Coverage
    • Number of Shares and Voting Rights
    • Newsletter to Shareholders
    • Shareholders' Meetings
    • Declaration of transactions performed on company securities
    • Liquidity Agreement
    • Public offerings - Documentation
    • Bonds Convertible into Shares (OCA)
  • Press releases
  • Investor relations
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

    

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home